CA2836478A1 - Proteines therapeutiques conjuguees avec des polymeres solubles dans l'eau par un groupe sulfhydryle de cysteine reduite - Google Patents
Proteines therapeutiques conjuguees avec des polymeres solubles dans l'eau par un groupe sulfhydryle de cysteine reduite Download PDFInfo
- Publication number
- CA2836478A1 CA2836478A1 CA2836478A CA2836478A CA2836478A1 CA 2836478 A1 CA2836478 A1 CA 2836478A1 CA 2836478 A CA2836478 A CA 2836478A CA 2836478 A CA2836478 A CA 2836478A CA 2836478 A1 CA2836478 A1 CA 2836478A1
- Authority
- CA
- Canada
- Prior art keywords
- therapeutic protein
- group
- peg
- protein
- soluble polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne des matériaux et des procédés pour conjuguer un polymère soluble dans l'eau à une protéine thérapeutique.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3012117A CA3012117A1 (fr) | 2011-05-27 | 2012-05-25 | Fusion de psa avec des serpines et autres proteines therapeutiques |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490869P | 2011-05-27 | 2011-05-27 | |
US61/490,869 | 2011-05-27 | ||
PCT/US2012/039637 WO2012166622A1 (fr) | 2011-05-27 | 2012-05-25 | Protéines thérapeutiques à plus longue demi-vie et leurs procédés de préparation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3012117A Division CA3012117A1 (fr) | 2011-05-27 | 2012-05-25 | Fusion de psa avec des serpines et autres proteines therapeutiques |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2836478A1 true CA2836478A1 (fr) | 2012-12-06 |
Family
ID=46208843
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3012117A Abandoned CA3012117A1 (fr) | 2011-05-27 | 2012-05-25 | Fusion de psa avec des serpines et autres proteines therapeutiques |
CA2836478A Abandoned CA2836478A1 (fr) | 2011-05-27 | 2012-05-25 | Proteines therapeutiques conjuguees avec des polymeres solubles dans l'eau par un groupe sulfhydryle de cysteine reduite |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3012117A Abandoned CA3012117A1 (fr) | 2011-05-27 | 2012-05-25 | Fusion de psa avec des serpines et autres proteines therapeutiques |
Country Status (7)
Country | Link |
---|---|
US (5) | US20120329127A1 (fr) |
EP (3) | EP3412314A1 (fr) |
JP (6) | JP2014520094A (fr) |
AU (5) | AU2012262428C1 (fr) |
CA (2) | CA3012117A1 (fr) |
TW (4) | TW201835109A (fr) |
WO (1) | WO2012166622A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103702699B (zh) | 2011-07-07 | 2016-08-17 | 诺沃—诺迪斯克有限公司 | 具有附加的剂量捕获和显示模块的药物输送注射笔 |
EP2825205A1 (fr) * | 2012-03-16 | 2015-01-21 | Belrose Pharma Inc. | Conjugués polymères d'inhibiteurs de la c1-estérase |
US9353165B2 (en) * | 2012-07-25 | 2016-05-31 | Grifols, S.A. | Purification of cell culture derived alpha1 protease inhibitor |
CN103333250A (zh) * | 2013-06-24 | 2013-10-02 | 上海大学 | 一种生物安全性好的纳米荧光探针的制备方法 |
WO2015086853A1 (fr) | 2013-12-13 | 2015-06-18 | Novo Nordisk Health Care Ag | Procédé de conjugaison thioéther de protéines |
US10046058B2 (en) | 2014-12-02 | 2018-08-14 | Rezolute, Inc. | Use of hydrophobic organic acids to increase hydrophobicity of proteins and protein conjugates |
CN107708679A (zh) | 2015-06-04 | 2018-02-16 | 安特里阿比奥有限公司 | 用于制备位点特异性蛋白质偶联物的胺聚乙二醇化方法 |
US10589615B2 (en) * | 2015-08-03 | 2020-03-17 | Ford Global Technologies, Llc | Decoupler for a hydraulic engine mount |
MA45473A (fr) * | 2016-04-04 | 2019-02-13 | Shire Human Genetic Therapies | Inhibiteur de c1 estérase conjugué et ses utilisations |
US11231415B2 (en) | 2016-05-12 | 2022-01-25 | Z Biotech Llc | Multivalent glycan microarray platform |
JP6773987B2 (ja) * | 2019-08-22 | 2020-10-21 | サミー株式会社 | 遊技機 |
AU2020338947A1 (en) | 2019-08-27 | 2022-03-31 | Tonix Pharma Limited | Modified TFF2 polypeptides |
JP6773989B2 (ja) * | 2019-09-09 | 2020-10-21 | サミー株式会社 | 遊技機 |
CN114652848A (zh) * | 2022-03-18 | 2022-06-24 | 山东大学齐鲁医院 | 一种peg化人血清白蛋白纳米材料及其制备方法和在肿瘤诊疗中的应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54113492A (en) | 1978-02-24 | 1979-09-05 | Sanyo Chem Ind Ltd | Preparation of glucoprotein derivative |
US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
US5621039A (en) | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
US6284874B1 (en) | 1994-06-17 | 2001-09-04 | Alpha Therapeutic Corporation | Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste |
WO1996040662A2 (fr) | 1995-06-07 | 1996-12-19 | Cellpro, Incorporated | Composes de liaison contenant un groupe aminooxy et leur utilisation pour la formation de conjugues |
US5616693A (en) | 1996-07-01 | 1997-04-01 | Alpha Therapeutic Corporation | Process for seperating alpha-1-proteinase inhibitor from COHN IV1 +1V4 paste |
NZ502375A (en) * | 1997-07-14 | 2001-11-30 | Bolder Biotechnology Inc | The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family |
WO1999003496A1 (fr) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Facteur ix antihemophilique presentant une activite de coagulation augmentee |
AU775937B2 (en) * | 1999-01-14 | 2004-08-19 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US7074878B1 (en) | 1999-12-10 | 2006-07-11 | Harris J Milton | Hydrolytically degradable polymers and hydrogels made therefrom |
US6413507B1 (en) | 1999-12-23 | 2002-07-02 | Shearwater Corporation | Hydrolytically degradable carbamate derivatives of poly (ethylene glycol) |
WO2001087922A2 (fr) | 2000-05-16 | 2001-11-22 | Lipoxen Technologies Limited | Derivatisation de proteines |
US7265084B2 (en) | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
KR100948532B1 (ko) | 2001-11-07 | 2010-03-23 | 넥타르 테라퓨틱스 | 분지형 중합체 및 그의 공액체 |
US7345150B2 (en) * | 2002-03-26 | 2008-03-18 | Medical University Of Toledo | Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use |
EP1681303B1 (fr) | 2002-09-11 | 2013-09-04 | Fresenius Kabi Deutschland GmbH | Polypeptides HASylés, en particulier érythropoiétine HASylée |
BR0314106A (pt) | 2002-09-11 | 2005-07-19 | Fresenius Kabi De Gmbh | Polipeptìdeos hasilados, especialmente eritropoietina hasilada |
PL1620118T3 (pl) | 2003-04-08 | 2014-11-28 | Yeda Res & Dev | Leki odwracalnie pegylowane |
SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
WO2005014655A2 (fr) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugues d'amidon d'hydroxyalkyle et de proteine |
EP1653991A2 (fr) | 2003-08-08 | 2006-05-10 | Fresenius Kabi Deutschland GmbH | Conjugues de polymere et de proteine lies au moyen d'un groupe de liaison oxime |
EP1654290B1 (fr) | 2003-08-12 | 2019-03-13 | Lipoxen Technologies Limited | Derive d'acide sialique destine a la derivatisation et a la conjugaison proteinique |
DE602004013021T3 (de) | 2003-09-22 | 2012-04-05 | Kamada Ltd. | Herstellung eines alpha-1-proteinaseinhibitors im grossmassstab und dessen verwendung |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
WO2005055946A2 (fr) | 2003-12-03 | 2005-06-23 | Neose Technologies, Inc. | Facteur de stimulation de colonies de granulocytes glycopegyle |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
EP1776389B1 (fr) | 2004-08-12 | 2016-06-29 | Lipoxen Technologies Limited | Dérivés d'acide sialique |
WO2006031811A2 (fr) | 2004-09-10 | 2006-03-23 | Neose Technologies, Inc. | Interferon alpha glycopegyle |
CN101124331B (zh) * | 2004-11-12 | 2013-04-24 | 拜尔健康护理有限责任公司 | Fvⅲ的位点定向修饰 |
PT1835938E (pt) | 2004-12-27 | 2013-11-06 | Baxter Int | Conjugados de polímero-factor de von willebrand |
KR101304157B1 (ko) | 2005-06-16 | 2013-09-06 | 넥타르 테라퓨틱스 | 분해가능한 결합을 갖는 컨주게이트 및 이러한 컨주게이트제조에 유용한 고분자 시약 |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
BRPI0708832A2 (pt) * | 2006-03-31 | 2011-06-14 | Baxter Int | construÇço proteinÁcea |
WO2008025856A2 (fr) | 2006-09-01 | 2008-03-06 | Novo Nordisk Health Care Ag | Protéines modifiées |
CA2704234A1 (fr) * | 2007-11-09 | 2009-05-14 | Baxter International Inc. | Facteur viii et facteur de von willebrand recombines modifies et procede d'utilisation |
AU2009239641B2 (en) * | 2008-04-24 | 2013-11-07 | Cantab Biopharmaceuticals Patents Limited | Factor IX conjugates with extended half-lives |
EP2326349B1 (fr) * | 2008-07-21 | 2015-02-25 | Polytherics Limited | Nouveaux réactifs et procédé destiné à conjuguer des molécules biologiques |
KR101912335B1 (ko) | 2009-07-27 | 2018-10-26 | 리폭센 테크놀로지즈 리미티드 | 비혈액 응고 단백질의 글리코폴리시알화 |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
CA2783000A1 (fr) * | 2009-12-16 | 2011-06-23 | Regentis Biomaterials Ltd. | Echafaudages formes de conjugues polymere-proteine, leurs procedes de generation et utilisations |
JP5767207B2 (ja) * | 2010-03-26 | 2015-08-19 | 協和発酵キリン株式会社 | 新規修飾部位導入抗体および抗体フラグメント |
-
2012
- 2012-05-25 US US13/481,260 patent/US20120329127A1/en not_active Abandoned
- 2012-05-25 EP EP18182890.6A patent/EP3412314A1/fr active Pending
- 2012-05-25 EP EP20197463.1A patent/EP3808378A1/fr not_active Withdrawn
- 2012-05-25 CA CA3012117A patent/CA3012117A1/fr not_active Abandoned
- 2012-05-25 WO PCT/US2012/039637 patent/WO2012166622A1/fr unknown
- 2012-05-25 AU AU2012262428A patent/AU2012262428C1/en active Active
- 2012-05-25 EP EP12725992.7A patent/EP2714093A1/fr not_active Withdrawn
- 2012-05-25 CA CA2836478A patent/CA2836478A1/fr not_active Abandoned
- 2012-05-25 JP JP2014512150A patent/JP2014520094A/ja active Pending
- 2012-05-28 TW TW107120205A patent/TW201835109A/zh unknown
- 2012-05-28 TW TW101118935A patent/TW201247709A/zh unknown
- 2012-05-28 TW TW106116645A patent/TWI714769B/zh not_active IP Right Cessation
- 2012-05-28 TW TW109123605A patent/TW202039006A/zh unknown
-
2017
- 2017-05-31 JP JP2017107268A patent/JP2017206513A/ja active Pending
- 2017-10-05 AU AU2017239551A patent/AU2017239551A1/en not_active Abandoned
-
2018
- 2018-06-15 AU AU2018204313A patent/AU2018204313A1/en not_active Abandoned
- 2018-06-26 JP JP2018120337A patent/JP2018162293A/ja active Pending
- 2018-07-11 US US16/033,042 patent/US20180318432A1/en not_active Abandoned
- 2018-07-11 US US16/033,044 patent/US20190142958A1/en not_active Abandoned
-
2019
- 2019-04-23 JP JP2019081408A patent/JP2019151643A/ja active Pending
- 2019-04-29 AU AU2019202970A patent/AU2019202970A1/en not_active Abandoned
- 2019-11-20 JP JP2019209238A patent/JP2020059717A/ja active Pending
-
2020
- 2020-10-05 US US17/063,116 patent/US20210106691A1/en not_active Abandoned
-
2021
- 2021-04-23 AU AU2021202508A patent/AU2021202508A1/en not_active Abandoned
- 2021-08-20 JP JP2021134697A patent/JP2021183636A/ja active Pending
-
2022
- 2022-02-22 US US17/677,926 patent/US20220175939A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20120329127A1 (en) | 2012-12-27 |
JP2021183636A (ja) | 2021-12-02 |
TWI714769B (zh) | 2021-01-01 |
WO2012166622A1 (fr) | 2012-12-06 |
US20190142958A1 (en) | 2019-05-16 |
AU2019202970A1 (en) | 2019-05-16 |
TW201731863A (zh) | 2017-09-16 |
EP3808378A1 (fr) | 2021-04-21 |
AU2017239551A1 (en) | 2017-10-26 |
AU2012262428C1 (en) | 2018-10-11 |
US20180318432A1 (en) | 2018-11-08 |
AU2018204313A1 (en) | 2018-07-05 |
JP2020059717A (ja) | 2020-04-16 |
EP2714093A1 (fr) | 2014-04-09 |
CA3012117A1 (fr) | 2012-12-06 |
TW201247709A (en) | 2012-12-01 |
US20220175939A1 (en) | 2022-06-09 |
TW201835109A (zh) | 2018-10-01 |
JP2014520094A (ja) | 2014-08-21 |
AU2012262428B2 (en) | 2017-07-06 |
EP3412314A1 (fr) | 2018-12-12 |
JP2018162293A (ja) | 2018-10-18 |
TW202039006A (zh) | 2020-11-01 |
US20210106691A1 (en) | 2021-04-15 |
EP3808378A8 (fr) | 2021-06-09 |
AU2021202508A1 (en) | 2021-05-20 |
JP2017206513A (ja) | 2017-11-24 |
JP2019151643A (ja) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210106691A1 (en) | Therapeutic proteins with increased half-life and methods of preparing same | |
JP5908401B2 (ja) | 血液凝固タンパク質複合体 | |
AU2012262428A1 (en) | Therapeutic proteins with increased half-life and methods of preparing same | |
ES2731626T3 (es) | Catalizadores nucleofílicos para enlace oxima | |
US10350301B2 (en) | Blood coagulation protein conjugates | |
JP2020111599A (ja) | オキシム連結のための求核触媒 | |
AU2015275284B2 (en) | Nucleophilic Catalysts for Oxime Linkage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |
Effective date: 20211220 |